APE1/Ref-1 as a Novel Target for Retinal Diseases

Area of Science:

• Biochemistry and Molecular Biology
• Ophthalmology
• Oncology

Background:

• APE1/Ref-1 (also called Ref-1) is a multifunctional protein involved in DNA repair and redox signaling.
• Ref-1 plays a critical role in regulating transcription factors (TFs) implicated in cancer and other diseases.
• Previous research has established Ref-1 as a drug target in various cancers.

Purpose of the Study:

• To explore the potential of targeting Ref-1's redox signaling function for treating retinal vascular diseases.
• To bridge findings from cancer studies of Ref-1 to its relevance in ocular diseases like diabetic retinopathy (DR), diabetic macular edema (DME), and neovascular age-related macular degeneration (nvAMD).
• To review current small molecules identified to inhibit Ref-1 activity.

Main Methods:

• Literature review and commentary synthesizing findings from cancer research to retinal disease applications.
• Analysis of Ref-1's role in regulating key TFs (HIF-1α, NF-κB, STAT3) involved in angiogenesis and inflammation.
• Identification and discussion of small molecule inhibitors targeting Ref-1, including those in clinical and preclinical development.

Main Results:

• Ref-1 regulates TFs (HIF-1α, NF-κB, STAT3) that control angiogenesis (VEGF) and inflammation, pathways crucial in DR, DME, and nvAMD.
• Inhibition of Ref-1 demonstrates potential therapeutic benefits by reducing inflammation and angiogenesis.
• Several small molecule inhibitors of Ref-1 have been identified, with APX3330 currently in clinical trials.

Conclusions:

• Targeting the Ref-1 redox signaling pathway presents a novel therapeutic strategy for retinal vascular diseases.
• Translational research from cancer studies provides a strong foundation for developing Ref-1 inhibitors for ocular indications.
• Ongoing development of Ref-1 inhibitors offers potential new treatments for conditions like diabetic retinopathy and macular degeneration.